Stockscreener 앱 받기
2.96
0.67%
-0.02
시간 외 거래:
3.00
0.04
+1.35%
전일 마감가:
$2.98
열려 있는:
$3.02
하루 거래량:
723.32K
Relative Volume:
0.88
시가총액:
$123.26M
수익:
$123.87M
순이익/손실:
$62.49M
주가수익비율:
1.773
EPS:
1.6695
순현금흐름:
$-87.53M
1주 성능:
-3.58%
1개월 성능:
-17.32%
6개월 성능:
-17.55%
1년 성능:
-38.08%
1일 변동 폭
$2.86
$3.05
1주일 범위
$2.86
$3.45
52주 변동 폭
$2.71
$7.34
아제너스 Stock (AGEN) Company Profile
명칭
Agenus Inc
전화
781-674-4410
주소
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
2.96 | 135.34M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
아제너스 Stock (AGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 개시 | Robert W. Baird | Outperform |
| 2023-02-28 | 재개 | H.C. Wainwright | Buy |
| 2022-09-28 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-04-22 | 개시 | B. Riley FBR | Buy |
| 2016-10-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 재확인 | Maxim Group | Buy |
| 2016-03-11 | 업그레이드 | Maxim Group | Hold → Buy |
| 2015-12-16 | 개시 | Jefferies | Buy |
| 2015-10-27 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-07-27 | 재확인 | MLV & Co | Buy |
| 2015-06-11 | 개시 | Oppenheimer | Outperform |
| 2015-01-12 | 재확인 | Maxim Group | Buy |
| 2015-01-09 | 재확인 | MLV & Co | Buy |
| 2015-01-09 | 재확인 | Maxim Group | Buy |
| 2014-12-19 | 재확인 | Maxim Group | Buy |
| 2014-05-08 | 재확인 | Maxim Group | Buy |
| 2014-03-14 | 재확인 | MLV & Co | Buy |
| 2013-10-08 | 재확인 | Maxim Group | Buy |
| 2012-01-05 | 개시 | William Blair | Outperform |
| 2011-12-01 | 개시 | Global Hunter Securities | Buy |
모두보기
아제너스 주식(AGEN)의 최신 뉴스
Are options traders betting on a big move in Agenus stock? - MSN
Why is Agenus (AGEN) down 9.6% since last earnings report? - MSN
Agenus Inc. (AGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? - Yahoo Finance
AGEN Early Access Revenues Signal a New Path Ahead of Approval - TradingView
Is Agenus Stock a Hold Amid Valuation and Funding Risks? - Yahoo Finance
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC - Yahoo Finance
Agenus Inc. (AGEN) Latest Press Releases & Corporate News - Yahoo Finance
Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
Garo H. Armen of Agenus (NASDAQ: AGEN) receives 4,644-share stock salary grant - Stock Titan
AGEN Stock Price, Quote & Chart | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential? - TradingView
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Agenus reports phase 1b liver cancer trial results By Investing.com - Investing.com India
Agenus (AGEN) Reports Phase 1b Results for Innovative Cancer Tre - GuruFocus
Agenus reports phase 1b liver cancer trial results - Investing.com UK
Agenus announces publication of Phase 1b BOT+BAL data - TipRanks
Agenus Announces Resignation of Principal Accounting Officer - TipRanks
Agenus Announces Publication of Phase 1b Botensilimab and Balstil - The National Law Review
Early drug combo yields responses in liver cancer after immunotherapy - Stock Titan
Agenus (AGEN) Principal Accounting Officer Austin Charette plans May 2026 exit - Stock Titan
아제너스 (AGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):